Maria Rogdaki

List of Publications by Year
in descending order

27 papers	1,032 citations	759233 12 h-index	610901 24 g-index
29 all docs	29 docs citations	29 times ranked	1630 citing authors

#	Article	IF	Citations
1	Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2018, 32, 3-29.	4.0	196
2	A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. JAMA Psychiatry, 2017, 74, 1206.	11.0	178
3	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications, 2020, 11, 246.	12.8	148
4	Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. Molecular Psychiatry, 2019, 24, 1502-1512.	7.9	120
5	The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. Biological Psychiatry, 2019, 85, 79-87.	1.3	54
6	Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. Journal of Psychopharmacology, 2015, 29, 892-897.	4.0	51
7	In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis. JAMA Psychiatry, 2019, 76, 1074.	11.0	50
8	Magnitude and heterogeneity of brain structural abnormalities in 22q11.2 deletion syndrome: a meta-analysis. Molecular Psychiatry, 2020, 25, 1704-1717.	7.9	39
9	Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. Psychopharmacology, 2019, 236, 1985-1997.	3.1	35
10	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational Psychiatry, 2021, 11, 393.	4.8	27
11	The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study. Molecular Psychiatry, 2021, 26, 1332-1345.	7.9	23
12	Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study. Scientific Reports, 2019, 9, 8685.	3.3	17
13	The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study. Psychiatry Research - Neuroimaging, 2019, 291, 34-41.	1.8	13
14	Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. Molecular Psychiatry, 2023, 28, 1995-2006.	7.9	13
15	Automated Data Quality Control in FDOPA brain PET Imaging using Deep Learning. Computer Methods and Programs in Biomedicine, 2021, 208, 106239.	4.7	13
16	The Topography of Striatal Dopamine and Symptoms in Psychosis: An Integrative Positron Emission Tomography and Magnetic Resonance Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1040-1051.	1.5	11
17	Glutamate connectivity associations converge upon the salience network in schizophrenia and healthy controls. Translational Psychiatry, 2021, 11, 322.	4.8	10
18	Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion. European Neuropsychopharmacology, 2019, 29, 1333-1342.	0.7	8

#	Article	IF	Citations
19	Neuroanatomical underpinnings of autism symptomatology in carriers and non-carriers of the 22q11.2 microdeletion. Molecular Autism, 2020, 11, 46.	4.9	8
20	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. British Journal of Psychiatry, 2022, 221, 740-747.	2.8	6
21	Treatment-Resistant Schizophrenia in a Patient With 17q12 Duplication. Biological Psychiatry, 2016, 80, e19-e20.	1.3	4
22	Patterns of Cortical Folding Associated with Autistic Symptoms in Carriers and Noncarriers of the 22q11.2 Microdeletion. Cerebral Cortex, 2020, 30, 5281-5292.	2.9	3
23	S181. THE STATE OR TRAIT COMPONENT OF DOPAMINE AND GLUTAMATE DYSFUNCTION IN THE RISK FOR PSYCHOSIS: AN IN VIVO MULTIMODAL IMAGING STUDY OF INDIVIDUALS WITH 22Q11.2 DELETION. Schizophrenia Bulletin, 2018, 44, S395-S395.	4.3	1
24	S84. THE EFFECT OF ANTIPSYCHOTICS ON GLUTAMATE LEVELS IN THE ANTERIOR CINGULATE AND CLINICAL RESPONSE MEASURED BY PANSS: A 1H-MRS STUDY IN FIRST-EPISODE PSYCHOSIS PATIENTS. Schizophrenia Bulletin, 2019, 45, S339-S339.	4.3	0
25	S172. GLUTAMATE RELATED CONNECTIVITY DISTURBANCES OF THE SALIENCE AND DEFAULT MODE NETWORKS IN PSYCHOSIS. Schizophrenia Bulletin, 2020, 46, S102-S103.	4.3	0
26	O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS. Schizophrenia Bulletin, 2020, 46, S28-S28.	4.3	0
27	M149. THE TOPOGRAPHY OF STRIATAL DOPAMINE AND SYMPTOMS IN PSYCHOSIS: AN INTEGRATIVE PET AND MRI STUDY. Schizophrenia Bulletin, 2020, 46, S192-S192.	4.3	0